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Summary The ability of pyrazinamide to enhance the in vivo cytotoxicity of cyclophosphamide in Lewis lung
and RIF- 1 tumours was investigated. Using an in vivo/in vitro excision assay a large single dose of
pyrazinamide (500 mg kg-' i.p.) was shown to enhance the tumour cell killing by cyclophosphamide. This
enhancement was greatest when pyrazinamide was administered before the alkylating agent and had a
dose-modifying effect on all cyclophosphamide doses tested, giving rise to a mean (± 1 s.e.) enhancement ratio
(ER) of 1.54 (± 0.15) for the Lewis lung and 1.24 (± 0.08) for the RIF-I tumour. Pyrazinamide also increased
the cytotoxic action ofcyclophosphamide in a normal tissue, namely white blood cell counts. However, the ER
was only 1.14 (± 0.08), which although not significantly different from the value seen in RIF-1 was
significantly less than the ER obtained with Lewis lung, suggesting the possibility of a therapeutic gain. This
benzamide analogue did not appear to inhibit recovery from cyclophosphamide-induced potentially lethal
damage in tumours, nor did it alter the bioactivation of cyclophosphamide or the subsequent clearance of the
cytotoxic species from the plasma, so the mechanism for this chemosensitisation remains unclear.
Pyrazinamide is a synthetic pyrazine analogue of nico-
tinamide (Weinstein, 1975a), which has been used as an
antimicrobial agent in the treatment of certain mycobacterial
infections, especially M. tuberculosis (Weinstein, 1975b).
Previous studies had demonstrated that this compound could
significantly enhance radiation damage in tumour cells in vivo
(Chaplin et al., 1990a). Structural analogues of pyrazinamide,
such as nicotinamide and various benzamide derivatives,
have also been shown to increase radiation damage in vitro
(Nduka et al., 1980; Brown et al., 1984a; Ben-Hur et al.,
1985) and in vivo (Calcutt et al., 1970; Jonsson et al., 1985,
Horsman et al., 1986a, 1989a; Brown et al., 1991; Kjellen et
al., 1991). These benzamide analogues will also enhance the
activity of various chemotherapeutic agents (Smulson et al.,
1977; Durkacz et al., 1980; Nduka et al., 1980; Durrant &
Boyle, 1982; Sakamoto et al., 1983; Boorstein & Pardee,
1984; Brown et al., 1984b; Jacobson et al., 1984; Horsman et
al., 1986b).
The current investigation was an attempt to determine
whether pyrazinamide also has any chemosensitising action in
vivo. Its ability to enhance cyclophosphamide damage in two
murine tumour systems (Lewis lung and RIF-1) and one
normal tissue (white blood cell counts) was studied in the
hope of demonstrating the presence of a therapeutic gain and
determining the possible mechanism(s) responsible.
Materials and methods
Tumour systems
Two tumour models, the RIF-1 sarcoma and the Lewis lung
carcinoma, were used in this study. Details of their derivation
and maintenance have been previously described (Twenty-
man et al., 1980; Chaplin et al., 1983). Solid tumours were
produced for experimental purposes by inoculating
2 x I05 cells either into the gastrocnemius muscle in the right
rear leg of 3- to 4-month-old female C3H/Km mice (RIF-1)
or by subcutaneous inoculation over the backs of C57BL/6
mice (Lewis lung). Treatments were carried out when the
tumour size was 100-600 mg.
Drug treatments
All drug solutions were prepared immediately prior to each
experiment. Pyrazinamide (Sigma, St Louis, MO, USA) was
dissolved in a sterile saline solution (0.9% sodium chloride)
and injected intraperitoneally (i.p.) into mice at an injection
volume of 0.02 ml per g body weight. Cyclophosphamide
(F.W. Horner, Montreal, Canada) was dissolved in sterile
water at various drug concentrations so that a constant
injection volume of 0.01 ml g-' body weight could be injected
i.p. into mice. Mice not receiving pyrazinamide or cyclophos-
phamide were injected with saline or sterile water.
Tumour studies
Tumour response was assayed by survival of tumour cells.
For the RIF-1 tumours, survival was determined as
previously described (Horsman et al., 1984), by excising
tumours at various times up to and including 24 h after
injecting cyclophosphamide. Two tumours were combined for
each data point. They were minced, enzymatically disagg-
regated to produce a single-cell suspension, centrifuged
(1,500 r.p.m.; 10 min) and the cells resuspended, counted,
serially diluted and plated in Waymouth's medium + 15%
fetal calf serum (Waymouth's + 15% FCS; Gibco, Santa
Clara, CA, USA) to determine their colony-forming ability.
Survival was expressed as surviving fraction per g of tumour.
This is the product of the plating efficiency and cell yield
per g of treated tumours relative to that for untreated cont-
rols. With the Lewis lung tumour, cell viability was assessed
using the soft-agar clonogenic assay (Courtenay, 1976). The
excision procedure was similar to that described for the
RIF-1 tumour model, except that cells were diluted and
plated in alpha medium + 20% FCS (Gibco). Survival was
also expressed as surviving fraction per g of tumour.
Bioassay
The ability of pyrazinamide to influence the bioactivation of
cyclophosphamide and the subsequent clearance of the
cytotoxic species from the plasma was investigated by expos-
ing tumour cells in culture to plasma from drug-treated
animals. Mice were injected with either saline or pyrazin-
amide prior to cyclophosphamide and at various times after
injecting the alkylating agent the mice were bled by cardiac
puncture under diethyl anaesthesia. The blood from 4-5
animals was combined and the plasma obtained by centri-
fugation (3,000 r.p.m.; 5 min) of heparinised whole blood.
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With RIF-1 tumour cells a 1 ml sample of plasma was mixed
with an equal volume of medium and then transferred to
60 mm Petri dishes containing the tumour cells. These cells
had been plated at a concentration of 1 x 106 cells per dish,
18 h before exposure to the plasma. After incubating with the
plasma for 3 h at 37°C in an atmosphere of air + 5% carbon
dioxide, the plates were rinsed once with 2 ml of Hanks'
balanced salt solution and exposed to 5 ml of 0.05% trypsin
(Omin at 37°C). The trypsin was subsequently removed by
centrifugation, the cells resuspended in fresh medium and
survival measured as outlined earlier. For the Lewis lung
tumour cells a similar procedure was used except that the
exposure to the plasma from drug-treated animals was per-
formed in suspension. A 1 ml volume of cells at a concentra-
tion of 1 x 106 cells ml-' was mixed with an equal volume of
plasma. The samples were then incubated at 37°C and
shaken. Following a 3 h exposure period, the samples were
centrifuged, the cells resuspended in fresh medium and then
plated in culture for estimation of survival as previously
described.
Body temperature measurements
Possible drug-induced temperature changes were determined
by measuring mouse body temperatures at various times after
injection with either pyrazinamide, cyclophosphamide or
both drugs together, using a rectally inserted thermocouple
(Bailey Instruments, Saddle Brooke, NJ, USA).
Normal tissue studies
Previous experiments have shown that the number of white
blood cells in the peripheral blood declines for several days
after treatment with cyclophosphamide (Law et al., 1981)
reaching a nadir level by 4 days, after which recovery begins.
In our experiments 5jll blood samples were therefore taken
from the tails of tumour-bearing mice 4 days after injecting
drugs. The blood was diluted with 95ptl of 2% glacial acetic
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acid to lyse the erythrocytes and the resulting suspension of
leucocytes counted using a haemocytometer.
Data analysis
Results were shown as either individual values or means
(± 1 s.e.) obtained from at least two independent
experiments. Lines through the data were generally the best
fits by eye, but for the tumour and normal tissue dose-
response curve linear regression analysis was used, with a
common intercept assumed for each pair of survival curves.
The regression analysis provided estimates of the slopes and
the standard error of these estimates. Enhancement ratios
(ERs) were determined as the ratio between the relevant
slopes, and the standard error of the ER was calculated using
the propagation-of-error technique. Statistical significance
was judged by comparing the estimate of a given parameter
with its standard error, the ratio having an appropriate
Student t-distribution.
Results
A single i.p. injection of pyrazinamide (500 mgkg-')
enhanced the cell killing produced by cyclophosphamide in
both the Lewis lung carcinoma and the RIF-I sarcoma
(Figure 1). This effect was dependent upon the time of
administration of each drug. For the Lewis lung tumour
maximum sensitisation occurred when the pyrazinamide was
injected 30 min before the cyclophosphamide, the effect de-
creasing as this time interval was increased, or if the
pyrazinamide was given at the same time or after the cyc-
lophosphamide. A similar result was observed in the RIF-I
tumour, although in this tumour model the greatest enhance-
ment was seen when the pyrazinamide and cyclophosphamide
were separated by a 2 h period. Pyrazinamide alone was
non-toxic to cells in both tumour systems.
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Figure 1 The effect of pyrazinamide (500 mg kg-' i.p.) administered at various times before (-) or after (+) a fixed i.p. dose of
cyclophosphamide. Tumour cell survival was assessed 18 h after giving the alkylating agent. (0) Pyrazinamide alone; (0)
pyrazinamide + cyclophosphamide. The shaded area represents the effects of cyclophosphamide alone (± I s.e.) at a dose of either
100 mg kg-' in Lewis lung or 75mgkg-' in RIF-1.650 M.R. HORSMAN & D.J. CHAPLIN
The effect of pyrazinamide on the survival response of
Lewis lung or RIF-I tumour cells exposed to different cyc-
lophosphamide doses in vivo is shown in Figure 2. In these
experiments tumour-bearing mice were injected with both
drugs separated by the time interval which gave the max-
imum enhancement in Figure 1. Cyclophosphamide alone
produced increasing amounts of cell kill with increasing dose
in both tumour systems. This tumour response to cyclophos-
phamide was further enhanced, in a dose-modifying fashion,
by pyrazinamide. The characteristics of the survival curves
are summarised in Table I. Clearly the slopes of the
pyrazinamide and cyclophosphamide curves are highly
significantly different from cyclophosphamide alone in both
tumour models (P<1 x 10-8), and the slope values obtained
resulted in enhancement ratios (ERs) of 1.54 (± 0.15) in the
Lewis lung tumour and 1.24 (± 0.08) in the RIF-1.
Figure 3 shows the effect on RIF-1 tumour cell survival of
varying the time of tumour removal from mice following
injection with cyclophosphamide (50 mg kg-'). The nadir of
cell killing was reached when tumours were excised as early
as 2 h after drug administration. If tumours were allowed to
remain in situ for longer time periods, survival increased,
consistent with repair. This repair appeared to be complete
by 24 h. As expected, pyrazinamide alone was non-toxic at
all time intervals measured. In addition, its enhancement of
the cyclophosphamide effect appeared to be simply a down-
ward parallel displacement of the survival curve.
Possible hypothermic effects of these treatments in mice
were investigated and the results are shown in Figure 4. It is
obvious that neither pyrazinamide, cyclophosphamide, nor
both agents together had any effect on mouse body
temperature. Since for the RIF-I tumour, grown intramus-
cularly in the leg of C3H mice, mouse body temperature is a
good indicator of tumour temperature (Horsman et al., 1984)
we can conclude that none of these drugs either alone or in
combination produced temperature changes in this tumour
model. Although we did not measure the temperatures in the
Lewis lung tumours grown in the flank of mice, we have no
reason to expect a difference with this system.
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The effect of pyrazinamide on the bioactivation of cyc-
lophosphamide and the subsequent disappearance of the
bioactivated species from the plasma was studied using sur-
vival of tumour cells in culture as the end point. The results
are shown in Figure 5. Plasma was removed at various times
from mice given either saline or pyrazinamide (500 mgkg-')
before cyclophosphamide (75 mg kg-1). This plasma was
subsequently transferred to tumour cells in culture, where it
remained in contact for 3 h. The results obtained with both
tumour cell lines showed that the greatest cell killing occur-
red with plasma taken 30 min after injecting cyclophos-
phamide. This cell killing decreased as time in the mouse
increased, with toxicity being lost by about 2 h. Injecting
pyrazinamide into mice prior to cyclophosphamide had no
additional influence on tumour cell survival.
Figure 6 shows the effect of combining pyrazinamide and
cyclophosphamide on a normal tissue. While blood cell
counts were determined 4 days after injecting the drugs, when
the nadir white blood cell levels are achieved following
alkylating agent administration (Law et al., 1981). Any possi-
ble effect of pyrazinamide on the subsequent recovery of the
white blood cell counts was not investigated. As shown in
Figure 6, the white blood cell counts were reduced by cyc-
lophosphamide in tumour-bearing mice, and this toxicity was
enhanced in a dose-modifying manner by the pyrazinamide.
The characteristics of these two survival curves are also
summarised in Table I. Although the ratio of the slope values
for the two curves only resulted in an ER of 1.14 (± 0.08),
the difference in these slope values was significant
(P<0.00l).
Discussion
Our current study has shown that pyrazinamide could sen-
sitise both the Lewis lung and RIF-I tumours to the
cytotoxic action of cyclophosphamide, the ERs obtained
being 1.54 (± 0.15) for Lewis lung and 1.24 (± 0.08) for
RIF-1. In the one normal tissue end point that was used,
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Figure 2 The effect of pyrazinamide (500 mg kg-' i.p.) on the response of Lewis lung or RIF-l tumours to cyclophosphamide
(i.p.). Pyrazinamide was injected either 30 min (Lewis lung) or 2 h (RIF-l) prior to the alkylating agent and tumour cell survival
was assayed 18 h later. (0) Cyclophosphamide alone; (0) pyrazinamide + cyclophosphamide.PYRAZINAMIDE CHEMOSENSITISATION 651
namely white blood cell counts, the ER was only 1.14
(± 0.08), which although not statistically significantly
different from the ER for the RIF-l tumour (P> 0.05) was
different from the ER obtained in Lewis lung (P<0.02). This
suggests the potential for a therapeutic gain.
Cell killing by a variety of chemotherapeutic agents has
been reported to be increased by structural analogues of
pyrazinamide both in vitro (Durkacz et al., 1980; Nduka et
al., 1980; Durrant & Boyle, 1982; Sakamoto et al., 1983;
Boorstein & Pardee, 1984; Brown et al., 1984b; Jacobson et
al., 1984) and in vivo (Smulson et al., 1977; Sakamoto et al.,
1983; Brown et al., 1984b; Horsman et al., 1986b). The
enhancement ofcytotoxicity in vitro has often been attributed
to an inhibition of drug-induced potentially lethal damage
(PLD) repair, but this may not explain the effects seen in
vivo. When RIF-l tumours were allowed to remain in situ
after drug injection, prior to estimation of tumour cell kill-
ing, it was clearly demonstrated that this tumour possessed
the ability to repair some of the damage induced by cyclo-
phosphamide (Figure 3). While pyrazinamide enhanced the
cell killing by this drug, it did so without inhibiting this PLD
repair. Similar results were previously reported by us in the
same tumour model using the alkylating agent melphalan
and the structural analogue of pyrazinamide, nicotinamide
(Horsman et al., 1986b). The enhancement of melphalan
cytotoxicity by nicotinamide, as well as by another analogue,
3-aminobenzamide, was almost entirely explained by a
decrease in the rate of clearance of melphalan from mouse
Table I Characteristics of the dose-response curves for cyclophosphamide alone or
cyclophosphamide and pyrazinamidea
Treatment" Intercept' Slope value Slope ratiod P value!
Lewis lung tumour
CYT alone - 0.039 (±0.003)f
1.47 (± 1.31) 1.54 (±0.15) <1 x 10-8
PYZ + CYT - 0.060 ( 0.003)
RIF-J tumour
CYT alone - 0.082 (± 0.004)
1.23 (± 1.26) 1.24 (±0.08) <1 x 10-8
PYZ + CYT -0.101 (±0.004)
WBC counts
CYT alone - 0.012 (+0.001)
5.80 (± 1.06) 1.14 (±0.08) <0.001
PYZ + CYT -0.013 (±0.001)
aResults are taken from the data shown in Figures 2 and 6. 'The treatments were
cyclophosphamide (CYT) ± pyrazinamide (PYZ), with the PYZ being injected 30 min (Lewis lung)
or 120 min (RIF-1 and WBC counts) prior to CYT. cEach pair of survival curves had the same
intercept. dThis is the ratio of the slopes for CYT alone and CYT + PYZ in each tissue. eRepresents
the significance level of the difference between the two sets of slope values. 'All values in parenthesis
are standard errors.
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Figure 3 Survival of RIF-1 tumour cells as a function of time
between cyclophosphamide administration and tumour removal.
(A) Pyrazinamide (500 mg kg-'); (0) cyclophosphamide
(50mgkg-'); t-) pyrazinamide 2 h before cyclophosphamide.
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Figure 4 Mouse body temperature as a function of time after
drug administration. Mice were injected with saline (S) or
pyrazinamide (P; 500mgkg-') 2h prior to water (W) or cyc-
lophosphamide (C; 75 mgkg-'). Results show means (± 1 s.e.)
for three mice from two separate experiments (different symbols).
The dashed lines represent the range of values measured in
control mice over the same time period.652 M.R. HORSMAN & D.J. CHAPLIN
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Figure 5 The effect of pyrazinamide (500 mgkg-') on the bioactivation of cyclophosphamide and the clearance of the cytotoxic
species from mouse plasma. Lewis lung or RIF-I tumour cells in culture were exposed for 3 h to plasma taken from mice at various
times after injection with cyclophosphamide (75mgkg-1). Tumour cell survival was assayed immediately after drug exposure. (O)
Cyclophosphamide alone; (0) pyrazinamide + cyclophosphamide. Pyrazinamide was injected 30 min before the alkylating agent in
C57 mice (Lewis lung) or 2h prior in C3H mice (RIF-1).
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Figure 6 Effect of pyrazinamide (500 mg kg-') on the number of
white blood cell (WBC) counts in C3H mice measured 4 days
after injection with different doses of cyclophosphamide. (0)
Cyclophosphamide alone; (-) pyrazinamide 2 h before cyc-
lophosphamide. Results show means (± 1 s.e.) for 5-6 mice per
group.
plasma, an effect which may have partially been a conse-
quence of hypothermia induced by both nicotinamide and
3-aminobenzamide. Pyrazinamide, on the other hand, had
no effect on mouse or tumour temperature (Figure 4). Fur-
thermore, it did not alter the bioactivation of cyclophos-
phamide, nor the clearance of this species from the plasma
(Figure 5), thus some other mechanism must account for the
chemosensitisation we observed.
No attempt was made by us to measure the pharmaco-
kinetics or uptake of cyclophosphamide in the tumour, so
any possible effect of pyrazinamide on these aspects cannot
be ruled out. However, one possible explanation for the
enhancement of the anti-tumour activity of cyclophos-
phamide by pyrazinamide may be improved drug delivery.
Pyrazinamide and related compounds are known to be in vivo
tumour radiosensitisers (Calcutt et al., 1970; Jonsson et al.,
1985; Horsman et al., 1986a, 1989a; Chaplin et al., 1990a;
Brown et al., 1991; Kjellen et al., 1991) and the mechanism
for this effect has been suggested to be due to an improve-
ment in tumour blood flow (Horsman et al., 1988, 1989b;
Chaplin et al., 1990a; Lee & Song, 1992). More specifically,
these agents actually improve oxygenation at the time of
irradiation by preventing the transient stoppages in micro-
regional blood flow (Chaplin et al., 1990a, b; Horsman et al.,
1990) which have been shown to result in the development of
acute hypoxia (Chaplin et al., 1986). It is unlikely that the
chemosensitisation produced by pyrazinamide in the current
study is a consequence of simply increasing the oxygenation
status of the tumour, since alkylating agents are generally
considered to be equally toxic to both aerobic and hypoxic
cells (Tannock & Guttman, 1981; Teicher et al., 1981),
although there is evidence that cells at reduced pH are more
sensitive (Chaplin et al., 1989), but in tumours these would
typically be diffusion-limited chronically hypoxic cells and
not those which are perfusion limited and thus acutely
hypoxic. However, acutely hypoxic cells may actually be
resistant to cyclophosphamide. The peak activity ofcytotoxic
species of cyclophosphamide in the plasma of both C3H and
C57 mice was within 30 min following drug injection, and by
90-120 min no active drug could be identified (Figure 5).
There is no definitive evidence showing exactly how long
transient stoppages in blood flow can last in tumours, but it
is possible that they could be of sufficient duration to
actually prevent adequate drug exposure to some cells. Thus,PYRAZINAMIDE CHEMOSENSITISATION 653
as a result of temporary blood flow cessations, the acutely
hypoxic cells may be protected from the cytotoxic action of
cyclophosphamide. With pyrazinamide preventing these tran-
sient stoppages in flow the cyclophosphamide may then be
able to reach cells in areas that perhaps normally it could
not.
Whatever the explanation for the enhancement of cyclo-
phosphamide cytotoxicity in tumours by pyrazinamide, this
benzamide derivative is clearly an interesting compound and
one that may have clinical applicability. In many respects it
seems to have effects which are almost identical to the struc-
tural analogue nicotinamide, and this compound is now
being considered for clinical testing as a radiation sensitiser.
Pyrazinamide has already been used in humans, primarily as
a secondary agent in the treatment of tuberculosis (Weins-
tein, 1975b). It is normally taken orally on a daily basis, in
several equally spaced doses, for periods which can last for
up to a few months. Side-effects limit the mean dose per day
to around 3 g (Weinstein, 1975a). How 3 g in humans com-
pares to the 500 mg kg-' mouse dose used in our current
study is not known. Detailed pharmacokinetic analyses of
nicotinamide in mice and humans have shown linear relation-
ships between dose administered and peak plasma concentra-
tions obtained, and that 3 g in humans resulted in the same
peak plasma levels as a single dose of 75 mg kg-' in mice
(Horsman et al., 1993). Whether pyrazinamide has the same
human to mouse relationship has not been determined. In
fact there is evidence to suggest that the pharmacokinetics of
pyrazinamide, at least in humans, differs dramatically from
that of nicotinamide, since oral doses of 1, 2 or even 3 g of
pyrazinamide have been reported to result in peak plasma
concentrations that do not increase with dose; instead they
appear to remain constant at around 40-50 tgml1I (Stott-
meier et al., 1968; Weiner & Tinker, 1972). Clearly, this is an
aspect that needs further investigation, as does additional in
vivo testing of pyrazinamide as a radio- and chemosensitiser
in other tumour models and appropriate normal tissues.
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